ARGININE DEIMINASE ENCAPSULATED IN ERYTHROCYTES, AND THEIR USE IN TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY Russian patent published in 2022 - IPC A61K38/50 A61K9/50 A61P43/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: first invention is the use of a pharmaceutical composition including arginine deiminase encapsulated in erythrocytes, independent of a co-factor, and a pharmaceutically acceptable carrier for the treatment of arginase-1 deficiency. The second invention is the use of a suspension of erythrocytes, in which co-factor-independent arginine deiminase is encapsulated, in the treatment of arginase-1 deficiency for reduction in arginine levels in plasma or blood of a patient suffering from arginase-1 deficiency for at least 50, 60, 70 or 80% during at least 6, 7, 8, 9, 10 or 11 days after the administration. The third invention is a method for the treatment of arginase-1 deficiency, including the administration of a pharmaceutical composition including arginine deiminase encapsulated in erythrocytes and a pharmaceutically acceptable carrier. The fourth invention is the use of erythrocytes, in which arginine deiminase is encapsulated, for the production of a drug for the treatment of arginase-1 deficiency.

EFFECT: group of inventions provides the possibility of treatment of arginase-1 deficiency, leading to a reduction in toxic accumulation of arginine and side products of its metabolism.

34 cl, 7 dwg, 7 tbl, 10 ex